CN111093623A - 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途 - Google Patents

药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途 Download PDF

Info

Publication number
CN111093623A
CN111093623A CN201780094129.5A CN201780094129A CN111093623A CN 111093623 A CN111093623 A CN 111093623A CN 201780094129 A CN201780094129 A CN 201780094129A CN 111093623 A CN111093623 A CN 111093623A
Authority
CN
China
Prior art keywords
lipid
peptide
pharmaceutical composition
therapeutic agent
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780094129.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·萨玛特
R·拉贾戈帕兰
A·沙玛
V·卡里亚普鲁马
G·韦尔
M·斯坦福
A·彭威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Vaccine Technology Co
Original Assignee
Immune Vaccine Technology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Vaccine Technology Co filed Critical Immune Vaccine Technology Co
Publication of CN111093623A publication Critical patent/CN111093623A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780094129.5A 2017-07-10 2017-11-09 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途 Pending CN111093623A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530498P 2017-07-10 2017-07-10
US62/530,498 2017-07-10
PCT/CA2017/051336 WO2019010560A1 (en) 2017-07-10 2017-11-09 PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN111093623A true CN111093623A (zh) 2020-05-01

Family

ID=65000992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780094129.5A Pending CN111093623A (zh) 2017-07-10 2017-11-09 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途

Country Status (7)

Country Link
US (1) US20200230057A1 (https=)
EP (1) EP3651733A4 (https=)
JP (1) JP7409594B2 (https=)
CN (1) CN111093623A (https=)
AU (1) AU2017423053A1 (https=)
CA (1) CA3069019A1 (https=)
WO (1) WO2019010560A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178677A1 (en) * 2018-03-20 2019-09-26 Immunovaccine Technologies Inc. Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
CN113966227B (zh) 2019-02-15 2025-10-10 克利夫兰诊所基金会 疫苗佐剂以及制剂
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING IT
EP3976092A1 (en) * 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
AU2021349286B2 (en) * 2020-09-24 2025-03-06 Nant Holdings Ip, Llc Vaccine compositions for mucosal immune response
US20230355526A1 (en) * 2020-09-28 2023-11-09 Immunovaccine Technologies Inc. Lipid compositions comprising polynucleotide antigens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998058A (zh) * 2011-10-06 2014-08-20 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN105188685A (zh) * 2013-03-15 2015-12-23 奎尔波特股份有限公司 用于制备脂质纳米颗粒的方法和装置
WO2017028811A1 (en) * 2015-08-19 2017-02-23 Shanghai Ginposome Pharmatech Co., Ltd. Liposomes with ginsenoside as membrane material and preparations and use thereof
WO2017083963A1 (en) * 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906110A (en) * 1959-09-29 Silencing attachment for seamless
US20060035853A1 (en) 2004-01-07 2006-02-16 Biomedical Research Models, Inc. Methods for tailoring the immune response to an antigen or immunogen
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
JP5429710B2 (ja) 2009-03-30 2014-02-26 独立行政法人放射線医学総合研究所 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
KR101102834B1 (ko) * 2010-02-24 2012-01-05 충남대학교산학협력단 신규한 리포좀 제조 방법 및 장치
CU20100144A7 (es) 2010-07-06 2012-06-21 Centro Inmunologia Molecular Composiciones vacunales a base de sticholisina encapsulada en liposomas
US20140199233A1 (en) 2011-05-11 2014-07-17 The Regents Of The University Of California Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
CA2853685C (en) * 2011-11-04 2019-09-03 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
RU2677658C2 (ru) 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита
WO2017097196A1 (zh) 2015-12-08 2017-06-15 正大天晴药业集团股份有限公司 脂质体的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998058A (zh) * 2011-10-06 2014-08-20 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN105188685A (zh) * 2013-03-15 2015-12-23 奎尔波特股份有限公司 用于制备脂质纳米颗粒的方法和装置
WO2017028811A1 (en) * 2015-08-19 2017-02-23 Shanghai Ginposome Pharmatech Co., Ltd. Liposomes with ginsenoside as membrane material and preparations and use thereof
WO2017083963A1 (en) * 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant

Also Published As

Publication number Publication date
JP2020526530A (ja) 2020-08-31
US20200230057A1 (en) 2020-07-23
EP3651733A1 (en) 2020-05-20
WO2019010560A1 (en) 2019-01-17
AU2017423053A1 (en) 2020-01-23
CA3069019A1 (en) 2019-01-17
EP3651733A4 (en) 2021-04-07
JP7409594B2 (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
AU2019226197B2 (en) Compositions and methods for delivery of biomacromolecule agents
JP7103726B2 (ja) 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用
JP6851983B2 (ja) デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
US20230000769A1 (en) Oil-in-water emulsion formulations for delivery of active or therapeutic agents
JP2018008964A (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
Khalifa et al. Subunit antigen delivery: emulsion and liposomal adjuvants for next-generation vaccines
US20220288181A1 (en) Antiviral vaccines using spherical nucleic acids
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
HK40035550A (en) Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
García et al. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review
WO2024186623A1 (en) Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) Methods of making lipid adjuvanted compositions
Rizzo et al. Poly (allylamine)/tripolyphosphate nanocomplex coacervate as a NLRP3-dependent systemic adjuvant for vaccine development
Udhayakumar Development and validation of synthetic-virus like vaccines
AU2022354218A1 (en) Survivin and mage-a9 dual-targeted immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200501

RJ01 Rejection of invention patent application after publication